Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs Ketogenic Diet in Refractory Epilepsy
NCT04542629Phase 4Unknown
- Sponsor
- Assiut University
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
01
Overview
Phase 4, randomised, open-label trial of rituximab in epilepsy (4 arms), sponsored by Assiut University. Primary endpoints: Seizure Frequency at 1 year, Antiepileptic Drugs at 1 year and 2 more. Status: unknown.
02
Drugs
rituximab
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT04542629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04542629.